CR20150603A - Metaloproteinasa de la matriz y usos del mismo - Google Patents

Metaloproteinasa de la matriz y usos del mismo

Info

Publication number
CR20150603A
CR20150603A CR20150603A CR20150603A CR20150603A CR 20150603 A CR20150603 A CR 20150603A CR 20150603 A CR20150603 A CR 20150603A CR 20150603 A CR20150603 A CR 20150603A CR 20150603 A CR20150603 A CR 20150603A
Authority
CR
Costa Rica
Prior art keywords
matrix
metaloproteinase
same
mmps
prommps
Prior art date
Application number
CR20150603A
Other languages
English (en)
Inventor
Claudia Zylberberg
Gregg B Fields
Original Assignee
Claudia Zylberberg
Gregg B Fields
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Claudia Zylberberg, Gregg B Fields filed Critical Claudia Zylberberg
Publication of CR20150603A publication Critical patent/CR20150603A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
    • C12N9/6405—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
    • C12N9/6416—Metalloendopeptidases (3.4.24)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24007—Interstitial collagenase (3.4.24.7), i.e. matrix metalloprotease 1 or MMP1
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24017—Stromelysin 1 (3.4.24.17)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24024—Gelatinase A (3.4.24.24), i.e. matrix metalloproteinase 2 or MMP2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24034—Neutrophil collagenase (3.4.24.34)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24035—Gelatinase B (3.4.24.35), i.e. matrix metalloprotease 9 or MMP9
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24065—Macrophage elastase (3.4.24.65), i.e. metalloelastase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Las realizaciones de la invención se dirigen a composiciones que comprenden una o más metaloproteinasas de matriz (MMPs), formas inactivas de MMPs (por ejemplo proMMPs), fragmentos, mutantes, variantes o combinaciones de los mismos. Una composición farmacéutica que comprende uno o más de los anteriores en un vehículo farmacéutico.
CR20150603A 2013-04-05 2015-11-05 Metaloproteinasa de la matriz y usos del mismo CR20150603A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361808861P 2013-04-05 2013-04-05
PCT/US2014/033009 WO2014165780A2 (en) 2013-04-05 2014-04-04 Matrix metalloproteinases and uses thereof

Publications (1)

Publication Number Publication Date
CR20150603A true CR20150603A (es) 2016-04-04

Family

ID=51659357

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20150603A CR20150603A (es) 2013-04-05 2015-11-05 Metaloproteinasa de la matriz y usos del mismo

Country Status (15)

Country Link
US (1) US20160053250A1 (es)
EP (2) EP2981276A4 (es)
JP (1) JP2016520550A (es)
KR (1) KR20160006694A (es)
CN (1) CN105246500A (es)
AU (1) AU2014248002A1 (es)
BR (1) BR112015025390A2 (es)
CA (1) CA2908739A1 (es)
CR (1) CR20150603A (es)
HK (1) HK1221405A1 (es)
MX (1) MX2015014053A (es)
PH (1) PH12015502306A1 (es)
RU (1) RU2015147878A (es)
SG (1) SG11201508199QA (es)
WO (1) WO2014165780A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105477627B (zh) * 2014-09-19 2021-04-30 山东蓝金生物工程有限公司 治疗前列腺癌的组合物及其用途
CN105477628B (zh) * 2014-09-19 2021-04-30 山东蓝金生物工程有限公司 抗癌组合物及其用途
CN105412917B (zh) * 2014-09-19 2021-04-30 达森生物药业有限公司 治疗实体瘤的抗癌组合物及其用途
CN105412916B (zh) * 2014-09-19 2021-04-30 达森生物药业有限公司 治疗乳腺癌的组合物及其用途
US20180265856A1 (en) * 2015-08-28 2018-09-20 Amano Enzyme Inc. Endotoxin-reduced thermolysin
CN105907840A (zh) * 2016-03-29 2016-08-31 苏州大学 单细胞水平检测mmp酶活性的方法
US10137179B2 (en) * 2016-05-18 2018-11-27 Hyalo Technologies, LLC Composition and method of preparation of protease microparticulate slow release preparation
CN108451981B (zh) * 2018-04-21 2019-07-23 江西汉氏联合干细胞科技有限公司 使用皮肤间充质干细胞治疗系统性硬化症
MX2021007422A (es) 2018-12-20 2021-12-10 The Steadman Clinic And Steadman Philippon Res Institute Metodos de matriz de tendon descelularizada y usos de los mismos.
CN114377150B (zh) * 2021-12-29 2023-10-13 中山大学南昌研究院 一种mmp酶敏感胎盘微环境和肿瘤微环境靶向载体及其制备方法和应用
CN116549325B (zh) * 2022-01-27 2025-07-29 南京大学 一种组合物、其制备方法、制剂及应用
CN119530138B (zh) * 2024-12-05 2026-01-30 中国肉类食品综合研究中心 一种用于工业化细胞解离的多酶制剂及其使用方法和应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5770691A (en) * 1995-06-05 1998-06-23 Regents Of The University Of Minnesota Discriminatory substrates for MMP hydrolysis
JP4335316B2 (ja) 1996-09-19 2009-09-30 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン アルギネートまたは修飾アルギネートのようなポリサッカライドを含むポリマー
US6531154B1 (en) 1997-06-10 2003-03-11 Brown University Research Foundation Modulated release from biocompatible polymers
US6248587B1 (en) 1997-11-26 2001-06-19 University Of Southern Cailfornia Method for promoting mesenchymal stem and lineage-specific cell proliferation
WO1999055396A1 (en) 1998-04-27 1999-11-04 Surmodics, Inc. Bioactive agent release coating
US6376742B1 (en) 1999-02-17 2002-04-23 Richard J. Zdrahala In vivo tissue engineering with biodegradable polymers
US6514515B1 (en) 1999-03-04 2003-02-04 Tepha, Inc. Bioabsorbable, biocompatible polymers for tissue engineering
KR100392501B1 (ko) 2000-06-28 2003-07-22 동국제약 주식회사 다중 에멀젼법에 의한 서방출성 미립구의 제조방법
US8252588B2 (en) * 2003-04-08 2012-08-28 Yeda Research And Development Co. Ltd. Stem cells having increased sensitivity to SDF-1 and methods of generating and using same
SE0302559D0 (sv) * 2003-09-25 2003-09-25 Astrazeneca Ab Method
AU2004280616A1 (en) * 2003-10-08 2005-04-21 Vet-Stem Inc. Methods of preparing and using stem cell compositions and kits comprising the same
WO2007079185A2 (en) * 2005-12-29 2007-07-12 Anthrogenesis Corporation Improved composition for collecting and preserving placental stem cells and methods of using the composition
WO2007117451A2 (en) * 2006-03-31 2007-10-18 The Regents Of The University Of Michigan A pericellular collagenase directs the 3-dimensional development of white adipose tissue
AU2008300185B2 (en) * 2007-09-19 2013-09-05 Pluristem Ltd. Adherent cells from adipose or placenta tissues and use thereof in therapy
US8222206B2 (en) * 2008-03-04 2012-07-17 Taiwan Advance Bio-Pharm Inc. Method of enhancing the mobilization of hematopoietic stem cells using TAT-HOXB4H
JP5572291B2 (ja) * 2008-04-07 2014-08-13 独立行政法人国立長寿医療研究センター 歯髄及び／又は象牙質形成促進のための薬剤及びその利用
EP2343087B1 (en) * 2008-09-30 2018-07-18 Oriental Yeast Co., Ltd. Novel inducer of chondrocyte proliferation and differentiation
EP2550006B1 (en) * 2010-03-24 2018-08-22 Lifenet Health Bmp-4 peptides&methods of use
PL2608809T3 (pl) * 2010-08-27 2019-10-31 Gilead Biologics Inc Przeciwciała dla metaloproteinazy 9 macierzy

Also Published As

Publication number Publication date
EP3290047A1 (en) 2018-03-07
WO2014165780A3 (en) 2014-12-18
JP2016520550A (ja) 2016-07-14
RU2015147878A (ru) 2017-05-10
BR112015025390A2 (pt) 2017-08-29
EP2981276A2 (en) 2016-02-10
WO2014165780A2 (en) 2014-10-09
CN105246500A (zh) 2016-01-13
US20160053250A1 (en) 2016-02-25
KR20160006694A (ko) 2016-01-19
PH12015502306A1 (en) 2016-02-15
AU2014248002A1 (en) 2015-11-19
SG11201508199QA (en) 2015-11-27
EP2981276A4 (en) 2017-03-22
HK1221405A1 (zh) 2017-06-02
MX2015014053A (es) 2016-04-07
CA2908739A1 (en) 2014-10-09

Similar Documents

Publication Publication Date Title
CR20150603A (es) Metaloproteinasa de la matriz y usos del mismo
CL2014002258A1 (es) Anticuerpos dirigidos contra metaloproteinasas de matriz 9 (mmp9 gelatinasa b); composicion farmaceutica que lo contiene; y sus usos.
CO2018006461A2 (es) Moléculas de anticuerpo contra april y usos de las mismas
MX2018004683A (es) Composicion detergente que comprende variantes de amilasa y proteasa.
CL2016000807A1 (es) Amino heteroarilo benzamidas como inhibidores de quinasa.
MX2019011764A (es) Composiciones limpiadoras y usos de las mismas.
BR112016020199A2 (pt) Composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso
CL2014003136A1 (es) Nuevos diazaespirocicloalcanos y azaespirocicloalcanos; composicion farmaceutica que los contiene y usos.
GT201600185A (es) Moléculas de anticuerpo que se unen a lag-3 y usos de las mismas
MX2015009105A (es) Composiciones en solucion solida y su uso en inflamacion cronica.
PE20151894A1 (es) Composiciones y metodos de variantes de inhibidor tisular de la metaloproteinasa tipo tres (timp 3)
MX2017010872A (es) Composiciones que comprenden combinaciones de cannabinoides purificados, con al menos uno de flavonoides, terpenos o minerales.
CR20140200A (es) Formas solidas de 3-(5-amino-2-metil-4-oxo-ah-quinazolin-3-il)-piperidin-2,6-diona, y sus composiciones farmaceuticas y sus usos
MX2016002166A (es) Anticuerpos.
CL2014002282A1 (es) Anticuerpos contra la metaloproteinasa de la matriz 9 (mmp9 gelatinasa b); composicion farmaceutica que la contiene; y sus usos.
MX2017009767A (es) Nuevas proteínas específicas para la angiogénesis.
CL2015003710A1 (es) Enlozador escindible por trombina con xten y usos del mismo
CO7250444A2 (es) Uso de seaprose para eliminar biopelículas bacterianas
MX2017012596A (es) Una composicion farmaceutica y el uso de la misma.
CL2016001210A1 (es) Análogos de bicalutamida o (s)- bicalutamida como compuestos activadores de la exocitosis para su uso en el tratamiento de un desorden de acúmulo lisosomal o glucogenosis.
EP3591038A4 (en) MESENCHYMATIC STEM CELL, AND PHARMACEUTICAL COMPOSITION
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
NI201500175A (es) Compuestos nuevos para el tratamiento del cáncer
BR112016017776A2 (pt) Formas sólidas de 2-(terc-butilamino)-4-((1r,3r,4r)-3-hidróxi-4-metil-ciclo-hexilamino)-pirimidina-5-carboxamida, composições das mesmas e métodos para seu uso
CR20170090A (es) Derivados de terahidroquinolina como inhibidores del bromodominio